Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01975831 | A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | completed | Phase 1 | 104 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02431559 | Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 53 | Ludwig Institute for Cancer ResearchOTHER | 2 | Oct 10, 2022 | clinicaltrials |
| NCT02788708 | Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | completed | Phase 1 | 26 | Floor BackesOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT03056833 | Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer | completed | Phase 1 | 35 | Ronald BuckanovichOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT02354131 | Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer(AVANOVA) | completed | Phase 1 / Phase 2 | 108 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 2 | Aug 30, 2022 | clinicaltrials |
| NCT01673217 | Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05476341 | A Phase I Clinical Trial of Bevacizumab Injection | completed | Phase 1 | 98 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 27, 2022 | clinicaltrials |
| NCT03029598 | Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT02977195 | First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors(NP137) | completed | Phase 1 | 70 | Centre Leon BerardOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT02475772 | A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis | completed | Phase 1 | 15 | Clemens TempferOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT03075462 | A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | completed | Phase 1 | 98 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03509636 | A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer | completed | Phase 1 | 113 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03023319 | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | completed | Phase 1 | 6 | Nagla Abdel KarimOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04088786 | Phase I Trial HIPEC With Nal-irinotecan | completed | Phase 1 | 18 | Stony Brook UniversityOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT02324439 | Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission | completed | Phase 1 | 15 | Southern Illinois UniversityOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT02646748 | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | completed | Phase 1 | 159 | Incyte CorporationINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02111850 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2022 | clinicaltrials |
| NCT02526017 | Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers(FPA008-003) | completed | Phase 1 | 313 | Five Prime Therapeutics, Inc.INDUSTRY | 1 | Mar 9, 2022 | clinicaltrials |
| NCT03985072 | Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor | completed | Phase 1 | 67 | Andes BiotechnologiesINDUSTRY | 1 | Feb 24, 2022 | clinicaltrials |
| NCT01554410 | Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma | completed | Phase 1 | 35 | University of California, San DiegoOTHER | 1 | Feb 17, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT00317772 | Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT00967577 | 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors | completed | Phase 1 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT04083196 | A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years | completed | Phase 1 | 90 | National Vaccine and Serum Institute, ChinaINDUSTRY | 1 | Nov 24, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT00989651 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 431 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2021 | clinicaltrials |
| NCT02914470 | Carboplatin-cyclophosphamide Combined With Atezolizumab(PROLOG) | completed | Phase 1 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Oct 19, 2021 | clinicaltrials |
| NCT04453241 | Immunogenicity and Safety Study of NBP615 in Healthy Female | completed | Phase 1 / Phase 2 | 200 | SK Bioscience Co., Ltd.INDUSTRY | 1 | Oct 1, 2021 | clinicaltrials |
| NCT02058550 | Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy | completed | Phase 1 | 72 | Stanford UniversityOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT03394885 | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer(AdORN) | completed | Phase 1 / Phase 2 | 18 | Duke UniversityOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT00574678 | Analyzing the Composition of Tears to Identify Cancer(ACT) | completed | Phase 1 / Phase 2 | 150 | University of ArkansasOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT02270606 | Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer | completed | Phase 1 | 14 | Virginia Commonwealth UniversityOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT03332576 | Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | completed | Phase 1 | 37 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 | clinicaltrials |
| NCT02303912 | Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer(ProGem2) | completed | Phase 1 | 25 | Imperial College Healthcare NHS TrustOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT02028117 | Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients(OCTAVE) | completed | Phase 1 | 38 | Akamis BioINDUSTRY | 2 | May 13, 2021 | clinicaltrials |
| NCT03205176 | AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | completed | Phase 1 | 49 | AstraZenecaINDUSTRY | 2 | May 6, 2021 | clinicaltrials |
| NCT02269293 | Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers | completed | Phase 1 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT01065662 | AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | completed | Phase 1 | 11 | Susana M. Campos, MDOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT03813940 | Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) | completed | Phase 1 | 24 | Xiamen UniversityOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT03507543 | The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors | completed | Phase 1 | 39 | Impact Therapeutics, Inc.INDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT03508011 | A Study of IMP4297 in Patients With Advanced Solid Tumors | completed | Phase 1 | 57 | Impact Therapeutics, Inc.INDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT03213964 | Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int | completed | Phase 1 | 10 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT01322802 | Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer | completed | Phase 1 | 25 | University of WashingtonOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT01989546 | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | completed | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2021 | clinicaltrials |
| NCT02172911 | A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer | completed | Phase 1 / Phase 2 | 10 | Inovio PharmaceuticalsINDUSTRY | 1 | Feb 21, 2021 | clinicaltrials |
| NCT01623349 | Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | completed | Phase 1 | 118 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT00003450 | Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer | completed | Phase 1 | — | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT02179515 | Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) | completed | Phase 1 | 38 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Oct 12, 2022source: clinicaltrials